A. Aitbaev¹, I. T. Murkamilov^2,3, Zh. A. Murkamilova³, V. V. Fomin⁴, I. O. Kudaibergenova², F. A. Yusupov⁵

¹Scientific-Research Institute of Molecular Biology and Medicine, Bishkek, Kyrgyzstan

²Kyrgyz State Medical Academy named after I. K. Akhunbaev, Bishkek, Kyrgyzstan

³Kyrgyz-Russian Slavic University, Bishkek, Kyrgyzstan

⁴First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia

⁵Osh State University, Osh, Kyrgyzstan

  Contact details:

Murkamilov Ilkhom Torokbekovich – PhD (medicine), acting Associate Professor of the Department of Faculty Therapy, Senior Lecturer of the Department of Therapy No. 2

Address: 92, Akhunbaev Str., Bishkek 720020, tel.: +996557221983, e-mail: murkamilov.i@mail.ru

 According to the criteria, post-COVID syndrome is a condition in which a patient’s symptoms persist for more than three weeks after being diagnosed with COVID-19. The article analyzes the current data on post-COVID syndrome with an emphasis on clinical manifestations, as well as on the problems associated with its treatment by primary health care professionals. The incidence of post-COVID syndrome is estimated at 10–35%, while for hospitalized patients it can reach 85%. Fatigue is the most common symptom, occurring in 17.5–72% of cases, followed by residual dyspnea (10–40%). Mental problems, chest pain, and olfactory and gustatory dysfunctions can affect up to 26%, 22% and 11% of patients, respectively. Published data indicate that more than a third of patients with post-COVID syndrome already had comorbidities, of which hypertension and diabetes mellitus were the most common. It has also been reported that the prognosis is good for most patients with post-COVID syndrome, with no further complications or deaths. Given the clinical spectrum of patients with post-COVID syndrome, most of them will be treated by primary health care professionals who play a key role in the management of patients with this syndrome. As the long-term consequences of COVID-19 remain largely unclear, further research is needed to elucidate the pathogenesis, clinical spectrum and prognosis of post-COVID syndrome.

Key words: COVID-19, SARS-CoV-2, post-infectious long-term complications, fatigue syndrome, treatment, primary health care, prevention.

REFERENCES

1. Hu B., Guo H., Zhou P. et al. Characteristics of SARS-CoV-2 and COVID. NatRevMicrobiol., 2020, vol. 19, no.3, pp.141–154.doi:10.1038/s41579-020-00459-7
2. Maxwell E. Living with Covid19: A dynamic review of the evidence around ongoing Covid19 symptoms (often called Long Covid), (updated 30th September 2020), avaialable at: https://evidence.nihr.ac.uk/themedreview/living-with-covid19/
3. Rubin R. As Their Numbers Grow, COVID-19 “Long Haulers” Stump Experts. JAM, 2020, vol. 324, no.14, pp.1381–1383.doi:10.1001/jama
4. Callard F., Perego E. How and why patients made Long Covid. Social Science & Medicine, 2021, vol. 268, pp. 113426.doi:10.1016/j.socscimed.2020.113426
5. Kingstone T., Taylor A.K., O’Donnell C.A. Finding the “right” GP: a qualitative study of the experiences of people with long-COVID. BJGP Open, 2020;4 bjgpopen20X101143. DOI: https://doi.org/10.3399/bjgpopen20X101143
6. Wiersinga W.J., Rhodes A., Cheng A.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA, 2020, vol. 324, pp.782–793. doi: 10.1001/jama.2020.12839
7. National Institute of Health Director’s blog. Post-covid syndrome, available at https://directorsblog.nih.gov/tag/post-covid-syndrome
8. Greenhalgh T., Knight M., A’Court M. Management of post-acute covid-19 in primary care. BM, 2020, vol. 370:m3026. doi:10.1136/bmj.m3026
9. Bhavana V., Thakor P., Singh S.B. COVID-19: pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV-2 pandemic. Life Sci., 2020, vol. 261.doi:10.1016/j.lfs.2020.118336
10. Alpert O., Begun L., Gerren P. Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines – two case reports. Brain Behav Immun Health., 2020, vol. 9. doi:10.1016/j.bbih.2020.100173
11. Tenforde M., Kim S., Lindsell C. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020. MMWR Morb Mortal Wkly Rep., 2020, vol. 69, pp. 993–998. doi:10.15585/mmwr.mm6930e1externalicon
12. Covid-19-long-term-health-effects, available at https://www.gov.uk/government/publications/covid-19-long-term-health-effects/covid-19-long-term-health-effects
13. Huang C., Huang L., Wang Y. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet, 2021, vol. 397, pp. 220–232. doi:10.1016/S0140-6736(20)32656-8
14. Simani L., Ramezani M., Darazam I.A. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. JNeurovirol., 2021, vol. 27, pp.154–159. doi:10.1007/s13365-021-00949-1
15. Carfi A., Bernabei R., Landi R. Persistent symptoms in patients after acute COVID-19. JAMA, 2020, vol. 324, pp.-603–605. doi:10.1001/jama.2020.12603
16. Addison A.B., Wong B., Ahmed T. Clinical Olfactory Working Group Consensus Statement on the Treatment of Post Infectious Olfactory Dysfunction. J Allergy Clin Immunol., 2021.doi: 10.1016/j.jaci.2020.12.641.S0091-6749(21)00004-X
17. Le Bon S.D., Pisarski N., Verbeke J. Psychophysical evaluation of chemosensory functions 5 weeks after olfactory loss due to COVID-19: a prospective cohort study on 72 patients. Eur Arch Otorhinolaryngol., 2020, vol. 278, pp. 101–108.doi:10.1007/s00405-020-06267-2
18. Moreno-Pérez O., Merino E., Leon-Ramirez J.M. COVID19-ALC research Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect., 2021. doi:10.1016/j.jinf.2021.01.004. S0163-4453(21)00009-8
19. Garg P., Arora U., Kumar A. The “post-COVID” syndrome: How deep is the damage? J Med Virol, 2021, vol. 93, pp. 673–674. doi:10.1002/jmv.26465
20. Liang L., Yang B., Jiang N. Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge. J Korean Med. Sci., 2020, vol.35, pp.-e418. doi: 10.3346/jkms.2020.35.e418
21. Moldofsky H., Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled stud. BMC Neurol., 2011, vol.11, pp. 37.doi:10.1186/1471-2377-11-37
22. Halpin S.J., McIvor C., Whyatt E.G. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol., 2021, vol. 93, pp. 1013–1022. doi:10.1002/jmv.26368
23. Carvalho-Schneider C., Laurent E., Lemaignen A. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect., 2021, vol. 27, pp. 258–263.doi:10.1016/j.cmi.2020.09.052
24. Garrigues E., Janvier P., Kherabi Y. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect., 2020, vol. 81, p. e4–e6. doi: 10.1016/j.jinf.2020.08.029
25. Davis H.E., Assaf G.S., McCorkell L. et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact, available at https://www.medrxiv.org/content/10.1101/2020.12.24.20248802v2
26. Bellan M., Soddu D., Balbo P.E. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. JAMA Netw Open, 2021, 4 doi:10.1001/jamanetworkopen.2020.36142
27. Soloveva N.V., Makarova E.V., Kichuk I.V. Coronavirus syndrome: COVID-19 psychotrauma. Eur J Transl Myol., 2021, vol. 30, 9302. doi:10.4081/ejtm.2020.9302
28. Chang M.C., Park D. Incidence of Post-Traumatic Stress Disorder After Coronavirus Disease. Health care (Basel), 2020, 8, 373. doi: 10.3390/healthcare8040373
29. Sher L. Post-COVID syndrome and suicide risk. QJM,2021:hcab007.doi: 10.1093/qjmed/hcab007
30. Ritchie K., Chan D., Watermeyer T. The cognitive consequences of the COVID-19 epidemic: collateral damage? Brain Commun., 2020, 2:fcaa069. doi:10.1093/braincomms/fcaa069
31. Raahimi M.M., Kane A., Moore C.E. Late onset of Guillain-Barre syndrome following SARS-CoV-2 infection: part of ‘long COVID-19 syndrome’? BMJ Case Rep., 2021,14 doi: 10.1136/bcr-2020-240178
32. Camdessanche J.P., Morel J., Pozzetto B. COVID-19 may induce Guillain-Barré syndrome. Rev Neurol (Paris), 2020, vol. 176, pp. 516–518. doi:10.1016/j.neurol.2020.04.003
33. Emamikhah M., Babadi M., Mehrabani M. Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. J Neurovirol., 2021, 1–9. doi:10.1007/s13365-020-00941-1
34. Scoppettuolo P., Borrelli S., Naeije G. Neurological involvement in SARS-CoV-2 infection: A clinical systematic review. Brain Behav Immun Health., 2020, 5 doi: 10.1016/j.bbih.2020.100094
35. Shahali H., Ghasemi A., Farahani R.H. Acute transverse myelitis after SARS-CoV-2 infection: a rare complicated case of rapid onset paraplegia. J Neurovirol., 2021, pp. 1–5. doi: 10.1007/s13365-021-00957-1
36. Kilbertus S. Acute transverse myelitis attributed to SARS-CoV-2 infection presenting as impaired mobility: a case report. CJEM, 2021. doi:10.1007/s43678-021-00104-z
37. Chopra V., Flanders S.A., O’Malley M. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Ann Intern Med., 2020, pp. M20–5661. doi:10.7326/M20-5661
38. Becker R.C. COVID-19 and its sequelae: a platform for optimal patient care, discovery and training. J Thromb Thrombolysis, 2021;1–8. doi: 10.1007/s11239-021-02375-w.
39. BelotserkovskayaYu.G., RomanovskikhA.G., SmirnovI.P., Sinopal’nikovA.I. Dolgiy COVID-19. Consilium Medicum, 2021, vol. 23, no. 3, pp. 261-268. DOI: 10.26442/20751753.2021.3.200805.
40. Kuz’mina A.E., Polina Yu.V. Postcoid syndrome, or «covid tail». Molodoy uchenyy, 2021, no. 22 (364), pp. 57-59 (in Russ.).
41. Souza C.D., Gois-Santos V.T., Correia D.S. The need to strengthen Primary Health Care in Brazil in the context of the COVID-19 pandemic. Braz Oral Res.,2020, vol. 34:e047. doi: 10.1590/1807-3107bor-2020.vol34.0047
42. Swankoski K.E., Peikes D.N., Palakal M. Primary care practice transformation introduces different staff roles. The Annals of Family Medicine, 2020, vol. 18, no. 3, pp. 227-234 (in Russ.) doi: 10.1370/afm.2515
43. Royal Australian College of General Practitioners. Caring for adult patients with post-COVID-19 conditions, available at: https://www.racgp.org.au/FSDEDEV/media/documents/RACGP/Coronavirus/Post-COVID-19-conditions.pdf
44. Holmes E.A., O’Connor R.C., Perry V.H. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry, 2020, vol. 7, pp. 547–560. doi:10.1016/S2215-0366(20)30168-1.
45. Office for National Statistics Analysis of death registrations not involving coronavirus (covid-19-19) England and Wales. June 2020, available at: https://www.ons.gov.uk/releases/analysisofdeathregistrationsnotassociatedwithcoronaviruscovid19englandandwalesjanuary2020tomay2020
46. Use of primary care during the COVID-19 pandemic. Patient-level data analysis of the impact of COVID-19 on primary care activity in England, available at https://www.health.org.uk/news-and-comment/charts-and-infographics/use-of-primary-care-during-the-covid-19-pandemic